RCEL vs APYX vs TELA vs SYK

For growth investors, TELA Bio, Inc.

(TELA) is the stronger pick with 18. 6% revenue growth year-over-year, versus 9. 9% for Apyx Medical Corporation (APYX). Stryker Corporation (SYK) offers the better valuation at 35. 0x trailing P/E (19. 6x forward), making it the more compelling value choice. Analysts rate AVITA Medical, Inc. (RCEL) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +21.

5%, compared to -91. 5% for TELA Bio, Inc. (TELA). Over 10 years, the gap is even starker: SYK returned +187. 1% versus TELA's -91. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.

55β versus Apyx Medical Corporation's 1. 96β — meaning APYX is approximately 258% more volatile than SYK relative to the S&P 500. On balance sheet safety, Stryker Corporation (SYK) carries a lower debt/equity ratio of 66% versus 3% for Apyx Medical Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TELA Bio, Inc.

(TELA) is pulling ahead at 18. 6% versus 9. 9% for Apyx Medical Corporation (APYX). On earnings-per-share growth, the picture is similar: Apyx Medical Corporation grew EPS 59. 1% year-over-year, compared to 8. 2% for Stryker Corporation. Over a 3-year CAGR, TELA leads at 33. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Stryker Corporation (SYK) is the more profitable company, earning 12.

9% net margin versus -67. 8% for AVITA Medical, Inc. — meaning it keeps 12. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RCEL leads at 89. 0% versus -49. 2% for TELA. At the gross margin level — before operating expenses — RCEL leads at 82. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for APYX: 68.

5% to $6. 00.

In this comparison, SYK (1.

1% yield) pays a dividend. RCEL, APYX, TELA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

55), 1. 1% yield, +187. 1% 10Y return). Apyx Medical Corporation (APYX) carries a higher beta of 1. 96 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +187. 1%, APYX: -45. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RCEL is a small-cap quality compounder stock; APYX is a small-cap quality compounder stock; TELA is a small-cap high-growth stock; SYK is a mid-cap quality compounder stock. SYK pays a dividend while RCEL, APYX, TELA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.